Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

AstraZeneca, Hutchmed Eye US Market for EGFR-MET Lung Cancer Combo

30 September 2026 · By · Wire by Fusion42

Published

30 September 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 30 September 2026 · Fusion42 review

AstraZeneca has filed for US FDA approval to market a combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) for EGFR-mutated advanced non-small cell lung cancer patients resistant to prior anti-EGFR treatment due to MET overexpression or amplification.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 29 Sep 2026 and 30 Sep 2026.

◆ ◆ The Wire takeaway

You face a new US regulatory hurdle and opportunity as AstraZeneca pushes a niche lung cancer combo therapy. Act fast to align clinical strategies and market entry plans in EGFR-mutated cancer segments.

◆ Coverage

2 sources · first reported 29 Sep 2026 · latest 30 Sep 2026

◆ Related on Wire

◆ Topics

BiotechFDA-approvallung-cancercombination-therapyoncologybiotech